Lower risk of HCC in chronic hepatitis B patients treated with tenofovir vs entecavir

Journal of Gastroenterology and HepatologyYuan BH, Li RH, Huo RR, et al. | January 27, 2022


i>NOTE, original article title: Lower risk of HCC with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: An updated meta‐analysis

In view of the controversial results from the previous smaller meta-analyses comparing the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) vs entecavir (ETV), researchers conducted this updated meta-analysis with the aim to reliably identify if TDF and ETV treated CHB patients, in general or in specific subgroups, differ in terms of the HCC incidence.

  • From PubMed, EMBASE, Web of Science, and Cochrane Library, researchers identified 24 comparative studies involving 37,771 CHB patients treated with TDF and 72,094 treated with ETV for inclusion.

  • Evidence gained suggests an association of TDF with significantly reduced HCC risk compared with ETV treatment in patients who are from Asia and/or nucleos(t)ide naïve.

Read the full article on Journal of Gastroenterology and Hepatology